Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$12.03
+0.27 (+2.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $76.8M · quality 62.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
100.3x
↑EV/EBITDA
25.5x
↑ROE
1.1%
↑Gross Margin
16.9%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-18.8%
FCF CAGR
-31.4%
FCF margin
9.8%
FCF / Net income
3.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $783.2M · net income $22.5M · FCF $76.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $783.2M | $783.2M | $838.8M | $972.9M | $1.46B |
| Net Income | $22.5M | $22.5M | $61.8M | $-12.3M | $140.3M |
| EBITDA | $127.7M | $127.7M | $184.3M | $141.6M | $277.3M |
| EPS | 0.08 | 0.08 | 0.21 | -0.04 | 0.48 |
| Gross Margin | 16.9% | 16.9% | 20.0% | 25.9% | 32.9% |
| Operating Margin | -0.3% | -0.3% | 4.6% | 1.2% | 11.0% |
| Net Margin | 2.9% | 2.9% | 7.4% | -1.3% | 9.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.02 | 0.01 | 0.02 |
| Current Ratio | 5.95 | 5.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $76.8M | $76.8M | $-12.3M | $100.5M | $238.2M |
| Returns | |||||
| ROE | 1.1% | 1.1% | 3.1% | -0.6% | 7.0% |
| Valuation | |||||
| P/E | 100.25 | 100.25 | 36.64 | — | 22.60 |
| EV/EBITDA | 25.48 | 25.48 | 10.76 | 18.46 | 10.59 |
| P/B | 1.75 | 1.75 | 1.14 | 1.48 | 1.57 |
| Growth & Yield | |||||
| Revenue Growth | -6.6% | -6.6% | -13.8% | -33.5% | — |
| EPS Growth | -62.9% | -62.9% | 601.4% | -108.8% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
139.5%
EPS terminal req.
$1.07
Spread vs growth
-202.4%
5Y implied EPS CAGR
75.4%
EPS terminal req.
$1.29
Spread vs growth
-138.4%
10Y implied EPS CAGR
38.9%
EPS terminal req.
$2.08
Spread vs growth
-101.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.1%
Start / end P/E
73.5x → 154.8x
EPS bridge
0.21 → 0.08
Residual
-69.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.